Teleconsultations Hypnosis Sessions for Patients With Peripheral Chronic Neuropathic Pain (HYPTEC)
Monocentric Pilot Study of the Feasibility of Teleconsultations Hypnosis Sessions Led by a Nurse for Patients With Peripheral Chronic Neuropathic Pain - HYPTEC
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jennie SOURZAC
- Phone Number: 0677551606
- Email: jennie.sourzac@chu-bordeaux.fr
Study Locations
-
-
Pessac
-
Pessac, Pessac, France, 33600
- Université Hospital, Bordeaux
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient aged over 18 years old,
- Patient suffering of from peripheral neuropathic pain for more than 1 year,
- Patient referred for hypnosis management as part of a coordinated care support,
- Patient who accepts teleconsultation, having the appropriate equipment to attend teleconsultations (computer, microphone, camera and stable internet connection with sufficient internet speed) and the ability to use it independently,
- Patient having signed a free, informed and written consent,
- Patient affiliated or beneficiary of the social security system.
Exclusion Criteria:
- Patient with severe and unstable neurocognitive or psychiatric conditions (depression, psychoses, major cognitive impairments),
- Patient with uncorrected deafness,
- Patient with poor understanding of French
- Patient placed under judicial safeguard, guardianship or curatorship.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: combination of face-to-face and teleconsultation hypnosis consultation
The first and the last hypnosis sessions in face-to-face, and the other 3 intermediate sessions being conducted by teleconsultation.
|
Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
To screen for anxious and depressive symptoms
Measurement of pain intensity
5 hypnosis consultation
Qualitative assessment
Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
|
|
Active Comparator: face-to-face hypnosis consultation
5 face-to-face hypnosis sessions
|
Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
To screen for anxious and depressive symptoms
Measurement of pain intensity
5 hypnosis consultation
Qualitative assessment
Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
5 hypnosis consultations (in face-to-face and by teleconsultation).
Time Frame: Month 8
|
The rate (%) of included patients who have completed the 5 hypnosis consultations (in face-to-face and by teleconsultation).
|
Month 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Achievement/Acceptability
Time Frame: Month 8
|
Acceptance rate (%) of the proposal to participate in the study in the two study arms: face-to-face hypnosis care (control arm) and care including hypnosis teleconsultations (experimental arm).
|
Month 8
|
|
Numerical Pain Assessme
Time Frame: Day 0, month 1, month 2, month 3 month 4 and montth 7
|
Mean difference in pain score, minimum value is 0 and maximum value is 10
|
Day 0, month 1, month 2, month 3 month 4 and montth 7
|
|
Hospital Anxiety and Depression scale (HAD)
Time Frame: Day 0, month 4 and month 7
|
Mean difference in the anxiety and depression score, minimum value is 0 and maximum value is 42
|
Day 0, month 4 and month 7
|
|
Learning self-hypnosis
Time Frame: Day 0, month 1, month 2, month 3 month 4 and montth 7
|
Evaluate the frequency of the use of self-hypnosis throughout the treatment.
|
Day 0, month 1, month 2, month 3 month 4 and montth 7
|
|
Ssatisfaction scale
Time Frame: Month 7
|
Evaluate the level of satisfaction and the feeling of the patients with regard to the nursing care in hypnosis at the end of the care in the two study arms (face-to-face control arm and experimental arm with teleconsultations).
|
Month 7
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jennie SOURZAC, Université Hospital, Bordeaux
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Neuromuscular Diseases
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain
- Peripheral Nervous System Diseases
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Therapeutics
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Health Care Facilities Workforce and Services
- Behavior Control
- Immobilization
- Restraint, Physical
- Maintenance
- Data Collection
Other Study ID Numbers
Other Study ID Numbers
- CHUBX 2022/34
- 2022-A02022-41 (Other Identifier: ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.